BIXTBIOXYTRAN, INCvs its industry peers
A metric-by-metric comparison of BIOXYTRAN, INC against Pharmaceutical Preparations — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BIXTThis | — | — | — | — | -22.5%#6 | 10.3%#9 | -964.3%#7 | — | — | — | — | — |
| BDRX | $318.4B#1 | — | — | — | — | — | — | — | — | — | -95.9%#5 | — |
| BEIGF | — | — | — | — | 40.2%#4 | 144.5%#2 | 8.4%#2 | 5.5%#1 | 29.9%#1 | 6#2 | — | — |
| BGM | — | — | — | — | 51.1%#2 | -1282.1%#11 | -33.2%#4 | -5.1%#2 | — | — | -96.3%#6 | — |
| BHST | $55M#4 | — | 2.2x#1 | 1.6x#1 | 37.0%#5 | 13.8%#8 | -16.2%#3 | -43.8%#5 | -216.8%#2 | — | -69.2%#4 | — |
| BIOE | — | — | — | — | 485.8%#1 | 168.5%#1 | 47.4%#1 | — | — | 8#1 | — | — |
| BIOM | — | — | — | — | — | 16.6%#7 | — | — | — | — | — | — |
| BLRX | $7.1B#2 | — | 391.7x#3 | 6040.3x#2 | -95.9%#7 | 78.0%#4 | -871.8%#6 | -11.1%#4 | — | — | -24.8%#2 | — |
| BLTE | $6.4B#3 | — | 8.4x#2 | — | — | -114.7%#10 | — | -10.1%#3 | — | — | 133.9%#1 | — |
| BQST | — | — | — | — | — | 64.7%#5 | — | — | — | — | — | — |
| BSPK | — | — | — | — | 42.3%#3 | 30.0%#6 | -89.0%#5 | — | — | — | — | — |
| BYSI | $36M#5 | — | — | — | — | 91.0%#3 | — | — | — | — | -55.8%#3 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-08-09.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice